Loading...
•
Jun 30, 2023
Palatin Technologies Q4 2023 Earnings Report
Announced fourth quarter and fiscal year ended 2023 financial results and provided corporate update.
Key Takeaways
Palatin Technologies reported its Q4 2023 financial results, with Vyleesi's net product revenue increasing by 47% and prescriptions dispensed increasing by 16% over the prior quarter. The Phase 3 PL9643 clinical study is fully enrolled, with interim analysis showing statistically significant positive effects on multiple endpoints.
PL9643 Phase 3 MELODY-1 clinical study patient enrollment completed.
Interim analysis of PL9643 data demonstrated statistically significant positive effects on multiple endpoints for both signs and symptoms, with excellent patient safety and tolerability.
Vyleesi's net product revenue increased 47% over the prior quarter.
Total prescriptions dispensed increased 16% over the prior quarter.
Palatin Technologies
Palatin Technologies
Forward Guidance
Palatin expects several key milestones in the coming quarters, including data readouts and study initiations.
Positive Outlook
- Topline Data Expected Late 4Q Calendar Year 2023
- Interim Analysis Targeted for 1Q Calendar Year 2024
- Topline Results Currently Expected First Half Calendar Year 2024
- Phase 2 clinical study in PDE5i non-responder ED patients is currently expected to commence late fourth quarter calendar year 2023.